These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18392053)

  • 1. Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women.
    Thomas R; Williams M; Marshall C; Walker L
    Br J Cancer; 2008 May; 98(9):1494-9. PubMed ID: 18392053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
    Kadakia KC; Kidwell KM; Seewald NJ; Snyder CF; Storniolo AM; Otte JL; Flockhart DA; Hayes DF; Stearns V; Henry NL
    Breast Cancer Res Treat; 2017 Jul; 164(2):411-419. PubMed ID: 28451964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
    ; Mouridsen H; Giobbie-Hurder A; Goldhirsch A; Thürlimann B; Paridaens R; Smith I; Mauriac L; Forbes J; Price KN; Regan MM; Gelber RD; Coates AS
    N Engl J Med; 2009 Aug; 361(8):766-76. PubMed ID: 19692688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
    Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
    Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
    Eisen A; Trudeau M; Shelley W; Messersmith H; Pritchard KI
    Cancer Treat Rev; 2008 Apr; 34(2):157-74. PubMed ID: 18164821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
    Stearns V; Chapman JA; Ma CX; Ellis MJ; Ingle JN; Pritchard KI; Budd GT; Rabaglio M; Sledge GW; Le Maitre A; Kundapur J; Liedke PE; Shepherd LE; Goss PE
    J Clin Oncol; 2015 Jan; 33(3):265-71. PubMed ID: 25512454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
    Nabholtz JM; Reese DM
    Breast Cancer; 2001; 8(4):305-9. PubMed ID: 11791122
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
    Le Rhun E; Delbeuck X; Lefeuvre-Plesse C; Kramar A; Skrobala E; Pasquier F; Bonneterre J
    Breast Cancer Res Treat; 2015 Aug; 152(3):569-80. PubMed ID: 26160250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.
    Boccardo F
    Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S13-7. PubMed ID: 15347434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aromatase inhibitors and arthralgia].
    Nagykálnai T; Landherr L; Mészáros E
    Magy Onkol; 2011 Mar; 55(1):32-9. PubMed ID: 21617789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
    Nagykálnai T
    Magy Onkol; 2008 Jun; 52(2):133-43. PubMed ID: 18640889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letrozole in the extended adjuvant setting: MA.17.
    Goss PE
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):45-53. PubMed ID: 17912635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
    Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
    Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
    Skedgel C; Rayson D; Dewar R; Younis T
    Breast; 2007 Jun; 16(3):252-61. PubMed ID: 17207623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.